<DOC>
	<DOCNO>NCT00437723</DOCNO>
	<brief_summary>This 2 arm study compare level anemia , decline renal function , patient receive NeoRecormon , receive . Patients chronic kidney disease , stage 2-4 , receive dialysis , randomize 2:1 group receive NeoRecormon ( dose determine investigator achieve maintain Hb level 120-135 g/L ) , control group receive NeoRecormon . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study NeoRecormon Patients With Chronic Kidney Disease .</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>adult patients,1875 year age ; endstage renal disease , dialysis ; Hb &lt; 110g/L . unstable hypertension ; acute infection ; use i.v . NeoRecormon , use ESA beside NeoRecormon ; myocardial infarction , unstable angina venous thrombosis within 6 month start treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>